Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer
Authors' conclusion
Anlotinib is generally well tolerated and can bring early disease control within the initial 6 weeks of treatment. The sharp biochemical response suggests Tg to be an early sensitive biomarker to anlotinib, whereas the heterogeneous metabolic response might play a complementary role.
Study context
- Population
- Patients with progressive RAI refractory DTC
- Participants
- 10 patients
- Outcome
- Early efficacy: structural response (RECIST 1.1), biochemical response (serum Tg) and metabolic response (18F-FDG PET/CT, EORTC criteria)
- Follow-up
- 6 weeks
Main finding
As reported in the abstract
Structurally controlled disease in all patients
20% partial response + 80% stable disease
Median longest diameter of target lesions, from baseline to 6 weeks
20.8 mm (IQR, 14.9-27.5) to 17.0 mm (IQR, 14.1-23.7)
P < .001
Average shrinkage rate
−15.1 ± 14.1%
Observational data: associations, not effects.
Further findings
Biochemical response: serum thyroglobulin (Tg) reduction · 6 weeks
- Serum Tg reduction in 8 measurable patients
- 72.8 ± 16.4%
Metabolic response (18F-FDG PET/CT) · 6 weeks
- Controlled metabolic disease
- 90% (30% partial metabolic response + 60% stable metabolic disease)
- Progressive metabolic disease
- 10%
Safety
Treatment-emergent adverse events (AEs)
- Hypertension
- 100%
- Proteinuria
- 70%
- Most AEs grade 1 or 2; grade 3 AEs only in hypertension
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →